Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 19/20 | 1.00 |
| ▸ | PBK | Q96KB5 | 4/20 | 1.00 |
| ▸ | CCNK | O75909 | 1/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547935 | 1.00 | NEK1 (1.00) | NEK1PBKCCNKCDK12 | |
| SCHEMBL30337717 | 1.00 | NEK1 (1.00) | NEK1PBKCCNKCDK12 | |
| SCHEMBL2547937 | 1.00 | NEK1 (1.00) | NEK1PBKCCNKCDK12 | |
| Hydrochloric Acid SCHEMBL15092181 | 0.99 | PBK (1.00) | NEK1PBKCCNKCDK12 | |
| Bromide SCHEMBL2553279 | 0.99 | NEK1 (0.98) | NEK1PBKCCNKCDK12 | |
| Bromide SCHEMBL2553276 | 0.99 | NEK1 (0.98) | NEK1PBKCCNKCDK12 | |
| Hydrochloric Acid SCHEMBL15092184 | 0.99 | PBK (1.00) | NEK1PBKCCNKCDK12 | |
| Hydrochloric Acid SCHEMBL16908853 | 0.99 | PBK (1.00) | NEK1PBKCCNKCDK12 | |
| SCHEMBL2546329 | 0.92 | NEK1 (0.85) | NEK1PBKCCNKCDK12 | |
| SCHEMBL2546327 | 0.92 | NEK1 (0.85) | NEK1PBKCCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060581-A1 | METHOD OF TREATING PANCREATIC CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2023-03-02 | — | — | US | claimed |
| EP-4103286-A1 | METHOD OF TREATING PANCREATIC CANCER | Cedars-Sinai Medical Center (US) | 2022-12-21 | — | — | EP | claimed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | claimed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | claimed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | claimed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | claimed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | claimed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | claimed |
| US-12440571-B2 | Immune agonists | SHENZHEN UNIVERSITY (CN) | 2025-10-14 | — | — | US | disclosed |
| WO-2024222483-A1 | ANTIBODY-CONJUGATED IMMUNO-ACTIVATING SMALL MOLECULE COMPOUND, AND USE | 深圳市康居正医药科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | disclosed |
| WO-2024010529-A1 | PRODUCTION OF ENANTIOPURE ALCOHOLS, AMINES AND ACIDS FROM RACEMIC EPOXIDES BY CASCADE BIOTRANSFORMATION INVOLVING EPOXIDE ISOMERIZATION AND DYNAMIC KINETIC RESOLUTION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-01-11 | — | — | WO | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12440571-B2 | Immune agonists | TLR7, TLR3, TLR1 | NEK1 2252/4885PBK 50/4885CCNK 3539/4885 |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | PBDC1, SBK1, PLK2 | NEK1 62/4885PBK 10/4885CCNK 152/4885 |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | PBDC1, SBK1, PLK2 | NEK1 62/4885PBK 10/4885CCNK 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.